{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T01:29:45Z","timestamp":1792114185809,"version":"4.4.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T00:00:00Z","timestamp":1722902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T00:00:00Z","timestamp":1722902400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Coagulation disorders are common in Kawasaki disease (KD). The main objectives of the present study were to probe the associations of coagulation profiles with clinical classification, IVIG responsiveness, coronary artery abnormalities (CAAs) in the acute episode of KD. A total of 313 KD children were recruited and divided into six subgroups, including complete KD (n\u2009=\u2009217), incomplete KD (n\u2009=\u200996), IVIG-responsive KD (n\u2009=\u2009293), IVIG-nonresponsive KD (n\u2009=\u200920), coronary artery noninvolvement KD (n\u2009=\u2009284) and coronary artery involvement KD (n\u2009=\u200929). Blood samples were collected within 24-h pre-IVIG therapy and 48-h post-IVIG therapy. Coagulation profiles, conventional inflammatory mediators and blood cell counts were detected. Echocardiography was performed during the period from 2- to 14-day post-IVIG infusion. In addition, 315 sex- and age-matched healthy children were enrolled as the controls. (1) Before IVIG therapy, coagulation disorders were more prone to appear in KD patients than in healthy controls, and could be overcome by IVIG therapy. FIB and DD significantly increased in the acute phase of KD, whereas reduced to normal levels after IVIG therapy. (2) PT and APTT were significantly longer in patients with complete KD when compared with their incomplete counterparts after IVIG therapy. (3) The larger \u03b4DD, \u03b4FDP and the smaller \u03b4PT, \u03b4INR predicted IVIG nonresponsiveness. (4) The higher \u03b4DD and \u03b4FDP correlated with a higher risk for CAAs (DD: <jats:italic>r<\/jats:italic>\u2009=\u2009\u22120.72, FDP: <jats:italic>r<\/jats:italic>\u2009=\u2009\u22120.54). Coagulation disorders are correlated with complete phenotype, IVIG nonresponsiveness and CAA occurrence in the acute episode of KD, and can be rectified by synergistic effects\u00a0of IVIG and aspirin.<\/jats:p>","DOI":"10.1007\/s10238-024-01430-z","type":"journal-article","created":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T13:08:23Z","timestamp":1722949703000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The changes of coagulation profiles in Kawasaki disease and its associations with clinical classification, intravenous immunoglobulin responsiveness and coronary artery involvement"],"prefix":"10.1007","volume":"24","author":[{"given":"Dao Ting","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cai Yun","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan Fang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu Qi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2144-9806","authenticated-orcid":false,"given":"Peng","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,6]]},"reference":[{"key":"1430_CR1","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jpeds.2020.05.034","volume":"225","author":"R Ae","year":"2020","unstructured":"Ae R, Makino N, Kosami K, Kuwabara M, Matsubara Y, Nakamura Y. Epidemiology, treatments, and cardiac complications in patients with Kawasaki disease: the nationwide survey in Japan, 2017\u20132018. J Pediatr. 2020;225:23-29.e2.","journal-title":"J Pediatr"},{"issue":"5","key":"1430_CR2","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1038\/ng.2227","volume":"44","author":"YC Lee","year":"2012","unstructured":"Lee YC, Kuo HC, Chang JS, et al. Two new susceptibility loci for Kawasaki disease identified through genome-wide association analysis. Nat Genet. 2012;44(5):522\u20135.","journal-title":"Nat Genet"},{"key":"1430_CR3","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.cca.2017.05.019","volume":"471","author":"P Hu","year":"2017","unstructured":"Hu P, Jiang GM, Wu Y, et al. TNF-\u03b1 is superior to conventional inflammatory mediators in forecasting IVIG nonresponse and coronary arteritis in chinese children with Kawasaki disease. Clin Chim Acta. 2017;471:76\u201380.","journal-title":"Clin Chim Acta"},{"issue":"2","key":"1430_CR4","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s10238-018-00544-5","volume":"19","author":"Y Wu","year":"2019","unstructured":"Wu Y, Liu FF, Xu Y, et al. Interleukin-6 is prone to be a candidate biomarker for predicting incomplete and IVIG nonresponsive Kawasaki disease rather than coronary artery aneurysm. Clin Exp Med. 2019;19(2):173\u201381.","journal-title":"Clin Exp Med"},{"issue":"4","key":"1430_CR5","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1007\/s10238-021-00709-9","volume":"21","author":"MM Niu","year":"2021","unstructured":"Niu MM, Jiang Q, Ruan JW, et al. Clinical implications of procalcitonin in Kawasaki disease: a useful candidate for differentiating from sepsis and evaluating IVIG responsiveness. Clin Exp Med. 2021;21(4):633\u201343.","journal-title":"Clin Exp Med"},{"issue":"1","key":"1430_CR6","doi-asserted-by":"publisher","first-page":"267","DOI":"10.5114\/aoms\/144293","volume":"18","author":"Z Qiu","year":"2021","unstructured":"Qiu Z, Liu HH, Fan GZ, Chen WX, Hu P. The clinical implications of serum ferritin in Kawasaki disease: a helpful biomarker for evaluating therapeutic responsiveness, coronary artery involvement and the tendency of macrophage activation syndrome. Arch Med Sci. 2021;18(1):267\u201374.","journal-title":"Arch Med Sci"},{"issue":"1","key":"1430_CR7","doi-asserted-by":"publisher","first-page":"16903","DOI":"10.1038\/s41598-021-96349-w","volume":"11","author":"L Xue","year":"2021","unstructured":"Xue L, Tao L, Li X, et al. Plasma fibrinogen, d-dimer, and fibrin degradation product as biomarkers of rheumatoid arthritis. Sci Rep. 2021;11(1):16903.","journal-title":"Sci Rep"},{"issue":"11","key":"1430_CR8","doi-asserted-by":"publisher","first-page":"3160","DOI":"10.1002\/art.38802","volume":"66","author":"F Minoia","year":"2014","unstructured":"Minoia F, Dav\u00ec S, Horne A, et al. Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients. Arthritis Rheumatol. 2014;66(11):3160\u20139.","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"1430_CR9","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1111\/jth.15216","volume":"19","author":"G Del Borrello","year":"2021","unstructured":"Del Borrello G, Giraudo I, Bondone C, et al. SARS-COV-2-associated coagulopathy and thromboembolism prophylaxis in children: a single-center observational study. J Thromb Haemost. 2021;19(2):522\u201330.","journal-title":"J Thromb Haemost"},{"issue":"7","key":"1430_CR10","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1111\/jth.15340","volume":"19","author":"M Al-Ghafry","year":"2021","unstructured":"Al-Ghafry M, Vagrecha A, Malik M, et al. Multisystem inflammatory syndrome in children (MIS-C) and the prothrombotic state: coagulation profiles and rotational thromboelastometry in a MIS-C cohort. J Thromb Haemost. 2021;19(7):1764\u201370.","journal-title":"J Thromb Haemost"},{"key":"1430_CR11","first-page":"1","volume":"00","author":"MM Niu","year":"2022","unstructured":"Niu MM, Jiang Q, Cao Y, et al. Tocilizumab in multisystem inflammatory syndrome in children (MIS-C)-summarized experiences. J Eur Acad Dermatol Venereol. 2022;00:1\u20134.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"17","key":"1430_CR12","doi-asserted-by":"publisher","first-page":"e927","DOI":"10.1161\/CIR.0000000000000484","volume":"135","author":"BW McCrindle","year":"2017","unstructured":"McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation. 2017;135(17):e927\u201399.","journal-title":"Circulation"},{"issue":"4","key":"1430_CR13","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1002\/art.42062","volume":"74","author":"LA Henderson","year":"2022","unstructured":"Henderson LA, Canna SW, Friedman KG, et al. American college of rheumatology clinical guidance for multisystem inflammatory syndrome in children associated With SARS-CoV-2 and hyperinflammation in pediatric COVID-19: version 3. Arthritis Rheumatol. 2022;74(4):e1\u201320.","journal-title":"Arthritis Rheumatol"},{"key":"1430_CR14","unstructured":"The Cardiovascular Group of the Chinese Society of Pediatrics, the Immunology Group of the Chinese Society of Pediatrics, and the Editorial Committee of the Chinese Journal of Pediatrics. Clinical management recommendations for coronary artery lesions in Kawasaki disease [J] CJP. 2012; 50(10):746\u201349 (In Chinese)."},{"key":"1430_CR15","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s12944-015-0167-2","volume":"14","author":"X Chen","year":"2015","unstructured":"Chen X, Zhao ZW, Li L, et al. Hypercoagulation and elevation of blood triglycerides are characteristics of Kawasaki disease. Lipids Health Dis. 2015;14:166.","journal-title":"Lipids Health Dis"},{"key":"1430_CR16","doi-asserted-by":"publisher","first-page":"257","DOI":"10.3109\/15513818509026899","volume":"4","author":"G Ohshio","year":"1985","unstructured":"Ohshio G, Furukawa F, Fujiwara H, Hamashima Y. Hepatomegaly and splenomegaly in Kawasaki disease. Pediatr Pathol. 1985;4:257\u201364.","journal-title":"Pediatr Pathol"},{"key":"1430_CR17","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/S0022-3476(05)80239-2","volume":"120","author":"B Bader-Meunier","year":"1992","unstructured":"Bader-Meunier B, Hadchouel M, Fabre M, Arnoud MD, Dommergues JP. Intrahepatic bile duct damage in children with Kawasaki disease. J Pediatr. 1992;120:750\u20132.","journal-title":"J Pediatr"},{"issue":"2","key":"1430_CR18","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.jhep.2014.08.050","volume":"62","author":"J Liu","year":"2015","unstructured":"Liu J, Tan Y, Zhang J, et al. C5aR, TNF-\u03b1, and FGL2 contribute to coagulation and complement activation in virus-induced fulminant hepatitis. J Hepatol. 2015;62(2):354\u201362.","journal-title":"J Hepatol"},{"issue":"2","key":"1430_CR19","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1159\/000368402","volume":"165","author":"Y Sakurai","year":"2014","unstructured":"Sakurai Y, Takatsuka H, Onaka M, Takada M, Nishino M. Persistent endothelial damage after intravenous immunoglobulin therapy in Kawasaki disease. Int Arch Allergy Immunol. 2014;165(2):111\u20138.","journal-title":"Int Arch Allergy Immunol"},{"issue":"1","key":"1430_CR20","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s10238-019-00596-1","volume":"20","author":"G Mammadov","year":"2020","unstructured":"Mammadov G, Liu HH, Chen WX, et al. Hepatic dysfunction secondary to Kawasaki disease: characteristics, etiology and predictive role in coronary artery abnormalities. Clin Exp Med. 2020;20(1):21\u201330.","journal-title":"Clin Exp Med"},{"issue":"11","key":"1430_CR21","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1111\/jth.12728","volume":"12","author":"A Undas","year":"2014","unstructured":"Undas A, Brummel-Ziedins K, Mann KG. Why does aspirin decrease the risk of venous thromboembolism? On old and novel antithrombotic effects of acetyl salicylic acid. J Thromb Haemost. 2014;12(11):1776\u201387.","journal-title":"J Thromb Haemost"},{"issue":"4","key":"1430_CR22","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1002\/art.41616","volume":"73","author":"LA Henderson","year":"2021","unstructured":"Henderson LA, Canna SW, Friedman KG, et al. American college of rheumatology clinical guidance for multisystem inflammatory syndrome in children associated with SARS-CoV-2 and hyperinflammation in pediatric COVID-19: version 2. Arthritis Rheumatol. 2021;73(4):e13\u201329.","journal-title":"Arthritis Rheumatol"},{"issue":"11","key":"1430_CR23","doi-asserted-by":"publisher","first-page":"5942","DOI":"10.1172\/JCI141113","volume":"130","author":"PY Lee","year":"2020","unstructured":"Lee PY, Day-Lewis M, Henderson LA, et al. Distinct clinical and immunological features of SARS-CoV-2-induced multisystem inflammatory syndrome in children. J Clin Invest. 2020;130(11):5942\u201350.","journal-title":"J Clin Invest"},{"issue":"6","key":"1430_CR24","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1111\/pai.13495","volume":"32","author":"S Shao","year":"2021","unstructured":"Shao S, Yang L, Liu X, et al. Predictive value of coagulation profiles for both initial and repeated immunoglobulin resistance in Kawasaki disease: a prospective cohort study. Pediatr Allergy Immunol. 2021;32(6):1349\u201359.","journal-title":"Pediatr Allergy Immunol"},{"issue":"2","key":"1430_CR25","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1007\/s12519-019-00234-6","volume":"15","author":"WX Kong","year":"2019","unstructured":"Kong WX, Ma FY, Fu SL, et al. Biomarkers of intravenous immunoglobulin resistance and coronary artery lesions in Kawasaki disease. World J Pediatr. 2019;15(2):168\u201375.","journal-title":"World J Pediatr"},{"issue":"7","key":"1430_CR26","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1097\/MPH.0b013e3181dccbf4","volume":"32","author":"GA Latino","year":"2010","unstructured":"Latino GA, Manlhiot C, Yeung RS, Chahal N, McCrindle BW. Macrophage activation syndrome in the acute phase of Kawasaki disease. J Pediatr Hematol Oncol. 2010;32(7):527\u201331.","journal-title":"J Pediatr Hematol Oncol"},{"issue":"2","key":"1430_CR27","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/S0022-3476(84)80114-6","volume":"105","author":"JC Burns","year":"1984","unstructured":"Burns JC, Glode MP, Clarke SH, Wiggins J Jr, Hathaway WE. Coagulopathy and platelet activation in Kawasaki syndrome: identification of patients at high risk for development of coronary artery aneurysms. J Pediatr. 1984;105(2):206\u201311.","journal-title":"J Pediatr"},{"issue":"3","key":"1430_CR28","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/S0022-3476(89)80859-5","volume":"115","author":"MP Glode","year":"1989","unstructured":"Glode MP, Joffe LS, Wiggins J Jr, Clarke SH, Hathaway WE. Effect of intravenous immune globulin on the coagulopathy of Kawasaki syndrome. J Pediatr. 1989;115(3):469\u201373.","journal-title":"J Pediatr"},{"issue":"2","key":"1430_CR29","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/1744-9987.12235","volume":"19","author":"Y Masuzawa","year":"2015","unstructured":"Masuzawa Y, Mori M, Hara T, Inaba A, Oba MS, Yokota S. Elevated D-dimer level is a risk factor for coronary artery lesions accompanying intravenous immunoglobulin-unresponsive Kawasaki disease. Ther Apher Dial. 2015;19(2):171\u20137.","journal-title":"Ther Apher Dial"},{"issue":"9930","key":"1430_CR30","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/S0140-6736(13)62298-9","volume":"383","author":"AH Tremoulet","year":"2014","unstructured":"Tremoulet AH, Jain S, Jaggi P, et al. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial. Lancet. 2014;383(9930):1731\u20138.","journal-title":"Lancet"},{"issue":"1","key":"1430_CR31","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1002\/art.41481","volume":"73","author":"I Kon\u00e9-Paut","year":"2021","unstructured":"Kon\u00e9-Paut I, Tellier S, Belot A, et al. Phase II open label study of anakinra in intravenous immunoglobulin-resistant Kawasaki disease. Arthritis Rheumatol. 2021;73(1):151\u201361.","journal-title":"Arthritis Rheumatol"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-024-01430-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-024-01430-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-024-01430-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T17:25:33Z","timestamp":1732987533000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-024-01430-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,6]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1430"],"URL":"https:\/\/doi.org\/10.1007\/s10238-024-01430-z","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,6]]},"assertion":[{"value":"13 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Approval for the present study was acquired from the Medical Ethic Committee of the First Affiliated Hospital of Anhui Medical University.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The consent was obtained from parents of all subjects.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"177"}}